See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Baseball
Natural Disasters
Social Media
Education
Senate
Taxes
Soccer
Tariffs
Artificial Intelligence
Donald Trump
Stock Markets
Republican Party
Published • loading... • Updated

Osimertinib OS Benefit Persists Among Patients With EGFR+ NSCLC

Summary by Medscape
OS for osimertinib vs placebo was 58.8 vs 54 months at the latest analysis of the phase 3 LAURA trial, according to late-breaking data presented at ELCC 2025. Medscape Medical News

5 Articles

All
Left
Center
Right
onclive.comonclive.com

FLAURA, FLAURA2, and MARIPOSA: Key Takeaways to Impact First-Line Treatment Approach

Panelists discuss how the FLAURA, FLAURA2, and MARIPOSA trials have reshaped first-line therapy for EGFR-mutant non–small cell lung cancer. FLAURA established osimertinib as superior to first-generation tyrosine kinase inhibitors. FLAURA2 showed added benefit with chemotherapy. MARIPOSA highlighted amivantamab-lazertinib as a strong alternative, refining treatment choices.

Read Full Article
MyChesCoMyChesCo

AstraZeneca Showcases TAGRISSO’s Potential in EGFR-Mutated Lung Cancer at ELCC 2025

WILMINGTON, DE — AstraZeneca presented new data on TAGRISSO® (osimertinib) at the European Lung Cancer Congress (ELCC) 2025, reinforcing its role as a backbone therapy across treatment stages for epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). Findings spanned multiple key trials, showcasing TAGRISSO’s effectiveness as both a standalone treatment and in combination therapies. Data from the Phase III LAURA tri…

Read Full Article
Anti-Aging, Acupuncture and Health NewsAnti-Aging, Acupuncture and Health News

Osimertinib OS Benefit Persists in NSCLC

Osimertinib (Tagrisso, AstraZeneca), continues to provide an overall survival (OS) benefit after definitive chemoradiotherapy (CRT) in patients with unresectable stage III epidermal growth factor receptor (EGFR)–mutated non–small cell lung cancer (NSCLC), according to the latest results from the pivotal phase 3 LAURA study. “This updated analysis…demonstrates an improved favorable trend for overall survival benefit with […] The post Osimertinib …

Read Full Article
MedscapeMedscape

Osimertinib OS Benefit Persists Among Patients With EGFR+ NSCLC

OS for osimertinib vs placebo was 58.8 vs 54 months at the latest analysis of the phase 3 LAURA trial, according to late-breaking data presented at ELCC 2025. Medscape Medical News

·United States
Read Full Article
cancernetwork.comcancernetwork.com

Osimertinib Shows Sustained Survival Benefit in EGFR-Mutant NSCLC

The safety profiles of osimertinib monotherapy and combination therapy were consistent with prior reports in EGFR-mutated non–small cell lung cancer.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

cancernetwork.com broke the news in on Sunday, March 30, 2025.
Sources are mostly out of (0)

Similar News Topics

Medical

Medical

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal